Search results for "Observation"

showing 10 items of 1586 documents

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in pati…

2012

Summary Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF). Replacement therapy with plasma-derived VWF/factor VIII (FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume-reduced (VR) formulation of VWF/FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled…

AdultMalePediatricsmedicine.medical_specialtyAdolescentBlood Loss SurgicalSevere diseaseHemorrhageSettore MED/15 - Malattie Del SangueYoung AdultVon Willebrand factorCost of Illnesshemic and lymphatic diseaseshemophiliavon Willebrand FactorVon Willebrand diseasemedicineHumansIn patientProspective StudiesDesmopressinAdverse effectChildGenetics (clinical)AgedFactor VIIIbiologybusiness.industryDrug SubstitutionAnticoagulantsHematologyGeneral MedicineMiddle Agedmedicine.diseaseResponse to treatmentHospitalizationvon Willebrand DiseasesItalyChild Preschoolbiology.proteinPasteurizationObservational studyFemalebusinessmedicine.drug
researchProduct

Public Health Relevance of Graves' Orbitopathy

2012

Disfiguring proptosis and functional impairment in patients with Graves' orbitopathy (GO) may lead to impaired earning capacity and to considerable indirect/direct costs.The aim of the study was to investigate the public health relevance of GO.This cross-sectional study was performed between 2005 and 2009 at a multidisciplinary university orbital center.A total of 310 unselected patients with GO of various degrees of severity and activity participated in the study.We conducted an observational study.We measured work disability and sick leave as well as the resulting indirect/direct costs of GO-specific therapies.Of 215 employed patients, 47 (21.9%) were temporarily work disabled, and 12 (5.…

AdultMalePediatricsmedicine.medical_specialtyCross-sectional studyEndocrinology Diabetes and MetabolismClinical BiochemistryPsychological interventionContext (language use)EfficiencyBiochemistryIndirect costsEndocrinologyCost of IllnessGermanySeverity of illnessHumansMedicinebusiness.industryPublic healthBiochemistry (medical)Health Care CostsMiddle AgedGraves OphthalmopathyCross-Sectional StudiesModels EconomicSick leaveCosts and Cost AnalysisPhysical therapyFemaleObservational studyPublic HealthSick LeavebusinessThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD: The CAT Study.

2016

Objective: The CAT ( Comorbilidad en Adultos con TDAH) study aimed to quantify and characterize the psychiatric comorbidity at the time of diagnosis of ADHD in adult outpatients. Method: Cross-sectional, multicenter, observational register of adults with ADHD diagnosed for the first time. Results: In this large sample of adult ADHD ( n = 367), psychiatric comorbidities were present in 66.2% of the sample, and were more prevalent in males and in the hyperactive-impulsive and combined subtypes. The most common comorbidities were substance use disorders (39.2%), anxiety disorders (23%), and mood disorders (18.1%). In all, 88.8% patients were prescribed pharmacological treatment for ADHD (in 9…

AdultMalePediatricsmedicine.medical_specialtyCross-sectional studySubstance-Related DisordersComorbidity03 medical and health sciencesPsychiatric comorbidity0302 clinical medicinemental disordersOutpatientsDevelopmental and Educational PsychologymedicinePrevalenceHumansSex DistributionPsychiatryMethylphenidatebusiness.industryMood DisordersMental Disordersmedicine.diseaseComorbidityAnxiety Disorders030227 psychiatryClinical PsychologyCross-Sectional StudiesMood disordersAttention Deficit Disorder with HyperactivityMethylphenidateAnxietyObservational studyFemalemedicine.symptomSubstance usebusiness030217 neurology & neurosurgerymedicine.drugJournal of attention disorders
researchProduct

PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the pe…

2015

BACKGROUND/AIMS: The epidemiology of Graves' orbitopathy (GO) may be changing. The aim of the study was to identify trends in presentation of GO to tertiary centres and initial management over time.METHODS: Prospective observational study of European Group On Graves' Orbitopathy (EUGOGO) centres. All new referrals with a diagnosis of GO over a 4-month period in 2012 were included. Clinical and demographic characteristics, referral timelines and initial decisions about management were recorded. The data were compared with a similar EUGOGO survey performed in 2000.RESULTS: The demographic characteristics of 269 patients studied in 2012 were similar to those collected in the year 2000, includi…

AdultMalePediatricsmedicine.medical_specialtyReferralEpidemiologyMedizin030209 endocrinology & metabolismGraves' ophthalmopathyTertiary Care Centers03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineEpidemiologymedicinePrevalenceHumansEpidemiology; Orbit; Ophthalmology; Sensory Systems; Cellular and Molecular NeuroscienceProspective StudiesProspective cohort studyReferral and Consultationbusiness.industryThyroid diseaseMiddle Agedmedicine.diseaseSensory SystemsEuropeGraves OphthalmopathyOphthalmologyCohort030221 ophthalmology & optometryObservational studyFemalesense organsPresentation (obstetrics)businessOrbitBritish journal of ophthalmology
researchProduct

Clinical and therapeutic features of myasthenia gravis in adults based on age at onset

2020

[Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG).

AdultMalePediatricsmedicine.medical_specialtyThymomagenetic structuresCross-sectional studyInvestigación médicaEnfermedad del sistema nerviosoMEDLINEMiastenia gravisLate onsetDISEASECLASSIFICATIONArticleACETYLCHOLINE-RECEPTOR03 medical and health sciences0302 clinical medicineimmune system diseasesMyasthenia GravismedicineEnfermedades neuromuscularesHumansRITUXIMAB030212 general & internal medicineAge of OnsetAgedbusiness.industryAnálisis de datosMiddle Agedmedicine.diseaseMyasthenia gravisnervous system diseasesCross-Sectional StudiesTreatment OutcomeMulticenter studyANTIBODIESAUTOANTIBODIESFemaleObservational studyNeurology (clinical)Age of onsetbusiness030217 neurology & neurosurgeryMUSK
researchProduct

MAGAM II – prospective observational multicentre poisons centres study on eye exposures caused by cleaning products

2019

Objective: Local effects on the eye following cleaning product exposures are frequently reported. According to EU chemicals legislation many cleaning products are labelled with Hazard Phrase 318 in...

AdultMalePoison Control CentersTime FactorsAdolescentgenetic structuresInjury controlAccident preventionDetergentsPoison controlToxicologyYoung Adult03 medical and health sciencesEye InjuriesInjury Severity Score0302 clinical medicineGermanyEnvironmental healthHumansMedicineProspective Studies030212 general & internal medicineChemical eye injuryChildAgedAged 80 and overbusiness.industryAge FactorsInfant030208 emergency & critical care medicineGeneral MedicineMiddle AgedCleaning product3. Good healthChild PreschoolFemaleObservational studybusinessProduct identificationClinical Toxicology
researchProduct

Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study

2009

AbstractObjectiveTo examine the predictive validity of early improvement in a naturalistic sample of inpatients and to identify the criterion that best defines early improvement.MethodsTwo hundred and forty-seven inpatients who fulfilled ICD-10 criteria for schizophrenia were assessed with the Positive And Negative Syndrome Scale (PANSS) at admission and at biweekly intervals until discharge from hospital. Remission was defined according to the recently proposed consensus criteria, response as a reduction of at least 40% in the PANNS total score from admission to discharge.ResultsReceiver operating characteristic (ROC) analyses showed that early improvement (reduction of the PANSS total sco…

AdultMalePredictive validitymedicine.medical_specialtyDrug trialAdolescentmedicine.medical_treatmentConsensus criteriaSensitivity and SpecificitySeverity of Illness Index03 medical and health sciences0302 clinical medicineNaturalistic observationInternational Classification of DiseasesInternal medicinemedicineHumans030212 general & internal medicinePsychiatryAntipsychoticAgedPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleReceiver operating characteristicPatient SelectionMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTranquilizing AgentsTreatment OutcomeROC CurveSchizophreniaArea Under CurveSchizophreniaFemalePsychologyAntipsychotic AgentsFollow-Up StudiesEuropean Psychiatry
researchProduct

The PACE study: Past-year prevalence of migraine in Parma's adult general population

2012

Background: In the literature there are few data about the prevalence of primary headaches, including migraine, in the Italian general population. The PACE study (PArma CEfalea, or ‘Headache in Parma’) is an observational study aimed at detecting the prevalence and clinical features of primary headaches in the city of Parma’s adult general population. Materials and methods: A total of 904 subjects representative of Parma’s adult general population were interviewed face-to-face by a physician from the Parma Headache Centre. They were given a specially designed and validated questionnaire for the diagnosis of primary headaches according to the ICHD-II criteria. Results: Past-year adjusted pr…

AdultMalePrevalence migrainePediatricsmedicine.medical_specialtyAdolescentUrban PopulationAuraMigraine DisordersPopulationRisk AssessmentYoung AdultAge DistributionChronic MigrainePrimary headacheRisk FactorsPrevalenceHumansMedicineSex DistributioneducationAgedAged 80 and overeducation.field_of_studybusiness.industryValidated questionnaireGeneral MedicineMiddle Agedmedicine.diseaseProbable migraineItalyMigraineFemaleObservational studySettore MED/26 - NeurologiaNeurology (clinical)business
researchProduct

Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey

2020

CF-COVID19-Spain Registry Group.

AdultMalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyPneumonia ViralPopulationDiseaseRisk AssessmentCystic fibrosisArticleCystic fibrosisBetacoronavirus03 medical and health sciencesCOVID-19 Testing0302 clinical medicinemedicineHumansRegistries030212 general & internal medicineMortalityeducationPandemicsRetrospective Studieseducation.field_of_studyClinical Laboratory Techniquesbusiness.industrySARS-CoV-2IncidenceIncidence (epidemiology)Mortality rateCOVID-19Retrospective cohort studymedicine.diseaseCoronavirus030228 respiratory systemSpainFemaleObservational studyCoronavirus InfectionsRisk assessmentbusiness
researchProduct

Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

2015

Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationCross-sectional studyOmalizumabOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioExhaled nitric oxide; Exacerbations; Comorbidities; Asthma; Omalizumab; ControlSeverity of Illness IndexComorbiditiesExacerbationsExhaled nitric oxideInternal medicineSeverity of illnessControlMedicineAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsInflammation MediatorAsthmaRespiratory Function TestAgedCross-Sectional Studiebusiness.industryBiochemistry (medical)ExacerbationMiddle Agedmedicine.diseaseComorbidityAsthmaRespiratory Function TestsCross-Sectional StudiesItalyExhaled nitric oxidePhysical therapyObservational studyAsthma; Comorbidities; Control; Exacerbations; Exhaled nitric oxide; Omalizumab; Adult; Aged; Anti-Asthmatic Agents; Asthma; Comorbidity; Cross-Sectional Studies; Female; Humans; Inflammation Mediators; Italy; Male; Middle Aged; Omalizumab; Respiratory Function Tests; Severity of Illness Index; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)FemaleComorbiditieInflammation Mediatorsbusinessmedicine.drugHuman
researchProduct